149 related articles for article (PubMed ID: 30895633)
1. Muir-Torre syndrome appropriate use criteria: Effect of patient age on appropriate use scores.
; Vidal CI; Sutton A; Armbrect EA; Lee JB; Litzner BR; Hurley MY; ; Alam M; Duncan LM; Elston DM; Emanuel PO; Ferringer T; Fung MA; Hosler GA; Lazar AJ; Lowe L; Plaza JA; Robinson JK; Schaffer A
J Cutan Pathol; 2019 Jul; 46(7):484-489. PubMed ID: 30895633
[TBL] [Abstract][Full Text] [Related]
2. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
3. Importance of universal mismatch repair protein immunohistochemistry in patients with sebaceous neoplasia as an initial screening tool for Muir-Torre syndrome.
Jessup CJ; Redston M; Tilton E; Reimann JD
Hum Pathol; 2016 Mar; 49():1-9. PubMed ID: 26826402
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
5. Analysis of Sebaceous Neoplasms for DNA Mismatch Repair Proteins in Muir-Torre Syndrome.
Pollinger TH; Kieliszak CR; Logemann N; Gratrix ML
Skinmed; 2017; 15(4):259-264. PubMed ID: 28859734
[TBL] [Abstract][Full Text] [Related]
6. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry, Molecular Biology, and Clinical Scoring for the Detection of Muir-Torre Syndrome in Cutaneous Sebaceous Tumors: Which Strategy?
Sinson H; Karayan-Tapon L; Godet J; Rivet P; Alleyrat C; Battistella M; Pierron H; Morel F; Lecron JC; Favot L; Frouin E
Dermatology; 2023; 239(6):889-897. PubMed ID: 37717564
[TBL] [Abstract][Full Text] [Related]
8. The significance of DNA mismatch repair genes in the diagnosis and management of periocular sebaceous cell carcinoma and Muir-Torre syndrome.
Gaskin BJ; Fernando BS; Sullivan CA; Whitehead K; Sullivan TJ
Br J Ophthalmol; 2011 Dec; 95(12):1686-90. PubMed ID: 21979897
[TBL] [Abstract][Full Text] [Related]
9. Screening for Muir-Torre syndrome using mismatch repair protein immunohistochemistry of sebaceous neoplasms.
Roberts ME; Riegert-Johnson DL; Thomas BC; Thomas CS; Heckman MG; Krishna M; DiCaudo DJ; Bridges AG; Hunt KS; Rumilla KM; Cappel MA
J Genet Couns; 2013 Jun; 22(3):393-405. PubMed ID: 23212176
[TBL] [Abstract][Full Text] [Related]
10. Sebaceous carcinoma epidemiology, associated malignancies and Lynch/Muir-Torre syndrome screening in England from 2008 to 2018.
Cook S; Pethick J; Kibbi N; Hollestein L; Lavelle K; de Vere Hunt I; Turnbull C; Rous B; Husain A; Burn J; Lüchtenborg M; Santaniello F; McRonald F; Hardy S; Linos E; Venables Z; Rajan N
J Am Acad Dermatol; 2023 Dec; 89(6):1129-1135. PubMed ID: 37031776
[TBL] [Abstract][Full Text] [Related]
11. Role of microsatellite instability, immunohistochemistry and mismatch repair germline aberrations in immunosuppressed transplant patients: a phenocopy dilemma in Muir-Torre syndrome.
Ponti G; Manfredini M; Pellacani G; Tomasi A
Clin Chem Lab Med; 2016 Nov; 54(11):1725-1731. PubMed ID: 27016151
[TBL] [Abstract][Full Text] [Related]
12. Muir-Torre Syndrome Associated Periocular Sebaceous Neoplasms: Screening Patterns in the Literature and in Clinical Practice.
Eiger-Moscovich M; Eagle RC; Shields CL; Racher H; Lally SE; Silkiss RZ; Shields JA; Milman T
Ocul Oncol Pathol; 2020 Aug; 6(4):226-237. PubMed ID: 33005611
[TBL] [Abstract][Full Text] [Related]
13. MSH-2 and MLH-1 protein expression in Muir Torre syndrome-related and sporadic sebaceous neoplasms.
Morales-Burgos A; Sánchez JL; Figueroa LD; De Jesús-Monge WE; Cruz-Correa MR; González-Keelan C; Nazario CM
P R Health Sci J; 2008 Dec; 27(4):322-7. PubMed ID: 19069357
[TBL] [Abstract][Full Text] [Related]
14. Muir-Torre syndrome (MTS): An update and approach to diagnosis and management.
John AM; Schwartz RA
J Am Acad Dermatol; 2016 Mar; 74(3):558-66. PubMed ID: 26892655
[TBL] [Abstract][Full Text] [Related]
15. The DNA mismatch repair system in sebaceous tumors: an update on the genetics and workup of Muir-Torre syndrome.
Dany M
Cutis; 2020 Mar; 105(3):E34-E37. PubMed ID: 32352449
[TBL] [Abstract][Full Text] [Related]
16. [Muir-Torre syndrome--a phenotypic variant of Lynch syndrome].
Kacerovská D; Kazakov DV; Cerná K; Hadravský L; Michal M; Dostál J; Skálová A; Michal M
Cesk Patol; 2010 Oct; 46(4):86-94. PubMed ID: 21313735
[TBL] [Abstract][Full Text] [Related]
17. Muir-Torre Syndrome and founder mismatch repair gene mutations: A long gone historical genetic challenge.
Ponti G; Manfredini M; Tomasi A; Pellacani G
Gene; 2016 Sep; 589(2):127-32. PubMed ID: 26143115
[TBL] [Abstract][Full Text] [Related]
18. Muir-Torre syndrome.
Bhaijee F; Brown AS
Arch Pathol Lab Med; 2014 Dec; 138(12):1685-9. PubMed ID: 25427047
[TBL] [Abstract][Full Text] [Related]
19. Sebaceous Neoplasms.
Flux K
Surg Pathol Clin; 2017 Jun; 10(2):367-382. PubMed ID: 28477886
[TBL] [Abstract][Full Text] [Related]
20. [Muir-Torre syndrome and Turcot syndrome].
Velter C; Caussade P; Fricker JP; Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):525-529. PubMed ID: 28256262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]